Highlights Cannara Biotech Inc. Canadian Securities Exchange

Equities

LOVE

CA13765U1012

Delayed Canadian Securities Exchange Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		-.--%	+87.50%

Apr. 29	Cannara Biotech Turns Negative As Reports Wider Q2 Net Loss Vs a Year Ago, Despite Revenue up 51%	MT
Jan. 29	Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cannara Biotech Turns Negative As Reports Wider Q2 Net Loss Vs a Year Ago, Despite Revenue up 51%	Apr. 29	MT
Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 29	CI
Cannara Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	Dec. 07	CI
Cannara Biotech's Fiscal Q4 Profit, Revenue Grows; Up 9.4%	Dec. 07	MT
Cannara Biotech Inc. Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	Dec. 07	CI
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	23-07-27	CI
Cannara Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-07-27	CI
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	23-04-24	CI
Cannara Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-04-24	CI
Cannara Biotech Down Near 8% As Enters into an Automatic Share Purchase Plan	23-02-28	MT
Cannara Biotech Converts CA$5 Million Debenture, Plus Interest, into Nearly 30 Million Shares for Olymbec Investments	23-02-10	MT
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	23-01-23	CI
Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022	23-01-23	CI
Cannara Biotech Reports Normal Course Issuer Bid for Common Shares	22-11-30	MT
Cannara Biotech Inc. announces an Equity Buyback for 15,000,000 shares, representing 1.71% of its issued share capital.	22-11-30	CI
Cannara Biotech Gains 5% as Q4 EPS Unchanged at $0.01 Vs Year Ago; Revenue $11.9 Million Vs $6.5 Million	22-11-25	MT
Cannara Biotech Q4 EPS Unchanged at $0.01 Vs Year Ago; Revenue $11.9 Million Vs $6.5 Million	22-11-25	MT
Cannara Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2022	22-11-25	CI
Cannara Biotech Inc. authorizes a Buyback Plan.	22-11-10	CI
Cannara Biotech Inc. Announces Entry into the British Columbia Market and the Launch of Its First Vape Cartridge and Vape Accessory, Tribal G Mint and Uni Pro Ark	22-09-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cannara Biotech Inc. Canadian Securities Exchange

Equities

LOVE

CA13765U1012

Highlights

Filters